Education
About Us
Working with TipRanks
Follow Us
Neuronetics (STIM)
:STIM
STIM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.52 - $5.92
Previous CloseN/A
Volume92.55K
Average Volume (3M)1.50M
Market Cap
$236.93M
Enterprise Value$126.10M
Total Cash (Recent Filing)-$17.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.53
Next Earnings
May 13, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding65,814,514
10 Day Avg. Volume1,237,018
30 Day Avg. Volume1,504,298
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.03
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.33
Enterprise Value/Ebitda-4.68
Forecast
1Y Price Target
$6.83Price Target Upside89.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Neuronetics News
PremiumCompany Announcements
Neuronetics’ Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Neuronetics Reports Growth Amid Strategic Acquisitions---
Bulls Say, Bears Say
Bulls Say
Acquisition BenefitsThe acquisition is already showing benefits, with STIM expecting to reach cash flow positivity in Q3, with 90% of the anticipated deal synergies realized by year-end.
Growth OpportunitiesNeuronetics is focusing on increasing the utilization of its systems and increasing revenue from SPRAVATO at Greenbrook clinics as key growth opportunities.
Bears Say
Financial PressureThe company continues to face headwinds, and the updated 2024 revenue and cash flow outlook exacerbated the pressure on the stock.
Operational ChallengesSTIM's second quarter reflected a top-line miss due to disruption from the Change Healthcare cybersecurity breach impacting the company's capital and treatment session sales.
---
Ownership Overview
14.75% Insiders
4.55% Mutual Funds
6.96% Other Institutional Investors
70.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STIM FAQ
What was Neuronetics’s price range in the past 12 months?
Neuronetics lowest stock price was $0.52 and its highest was $5.92 in the past 12 months.
What is Neuronetics’s market cap?
Neuronetics’s market cap is $236.93M.
When is Neuronetics’s upcoming earnings report date?
Neuronetics’s upcoming earnings report date is May 13, 2025 which is in 38 days.
How were Neuronetics’s earnings last quarter?
Neuronetics released its earnings results on Mar 04, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.242 by -$0.088.
Is Neuronetics overvalued?
According to Wall Street analysts Neuronetics’s price is currently Undervalued.
Does Neuronetics pay dividends?
Neuronetics does not currently pay dividends.
What is Neuronetics’s EPS estimate?
Neuronetics’s EPS estimate is -0.12.
How many shares outstanding does Neuronetics have?
Neuronetics has 65,814,514 shares outstanding.
What happened to Neuronetics’s price movement after its last earnings report?
Neuronetics reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.242. Following the earnings report the stock price went up 18.779%.
Which hedge fund is a major shareholder of Neuronetics?
Currently, no hedge funds are holding shares in STIM
---
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.83 (89.72% Upside)
$6.83 (89.72% Upside)
Blogger Sentiment
Bullish
STIM Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $666.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.26%
12-Months-Change
Fundamentals
Return on Equity
-139.60%
Trailing 12-Months
Asset Growth
21.65%
Trailing 12-Months
Company Description
Neuronetics
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
---
STIM Company Deck
---
STIM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements, including revenue growth, a transformative acquisition, and successful program implementations. However, challenges such as decreased gross margins, increased operating expenses, and a net loss were also noted. The company is confident in its growth strategy for 2025.Read More>---
STIM Stock 12 Month Forecast
Average Price Target
$6.83
▲(89.72% Upside)
Technical Analysis
Best Analysts Covering STIM
1 Year
1 Year Success Rate
7/20 ratings generated profit
1 Year Average Return
+19.41%
reiterated a buy rating last month
Copying William Plovanic's trades and holding each position for 1 Year would result in 35.00% of your transactions generating a profit, with an average return of +19.41% per trade.
---